// App-Quantinova.ai

THU0519 : OPTIMAL USE OF CONTRAST ENHANCED MRI FOR CLINICAL TRIALS OF INFLAMMATORY DISEASES: RETROSPECTIVE ANALYSIS OF DATA FROM A PHASE IIB STUDY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

Researchers

Presenter

  • M. Boesen

Principal Investigators

  • M. Hinton

  • J. Gonzalez-Zabaleta

  • S. Beattie

  • D. Schlichting

  • T. Rooney

  • O. Kubassova

Medical Centers

  • University Hospital Bispebjerg-Frederiksberg, Copenhagen, Denmark

  • Image Analysis Group, Philadelphia, United States of America

  • Image Analysis, London, United Kingdom

  • Eli Lilly and Company, Indianapolis, United States of America

Locations

  • Denmark

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT01185353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved